title: New targets in systemic lupus (part 2/2).
abstract: Glucocorticoids, aspirin, conventional antimalarials and immunosuppressants are the mainstay of treatment of Systemic Lupus Erythematosus (SLE). Until recently, the first three were the only agents approved for treatment. A better understanding of the pathophysiology of the immune system has identified new therapeutic targets. In fact, belimumab, a human monoclonal antibody to BLyS inhibitor has become, in recent months, the first drug approved for the treatment of SLE since 1957, underscoring difficulties of all kinds, including economic and organizational ones inherent to clinical trials on this disease. Many other molecules are in various stages of development and soon will have concrete results. In this review, we examined the mechanism of action and most relevant clinical data for these molecules.
authors.affiliation: Servicio de Reumatología, Hospital Universitario Ramón y Cajal, Madrid, Spain.
authors.forename: Walter A
authors.initials: WA
authors.lastname: Sifuentes Giraldo
authors.forename: María J
authors.initials: MJ
authors.lastname: García Villanueva
authors.forename: Alina L
authors.initials: AL
authors.lastname: Boteanu
authors.forename: Ana
authors.initials: A
authors.lastname: Lois Iglesias
authors.forename: Antonio C
authors.initials: AC
authors.lastname: Zea Mendoza
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000917:Antibody Formation / Q000187:drug effects; D017209:Apoptosis / Q000187:drug effects; D053264:B-Cell Activating Factor / Q000037:antagonists & inhibitors / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000473:pathology; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D008211:Lymphocyte Cooperation / Q000187:drug effects; D038041:Lymphopoiesis / Q000187:drug effects; D058990:Molecular Targeted Therapy; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex / Q000187:drug effects; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology; D014157:Transcription Factors / Q000037:antagonists & inhibitors; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13 / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D053264:B-Cell Activating Factor; D015815:Cell Adhesion Molecules; D016207:Cytokines; D007166:Immunosuppressive Agents; D047908:Intracellular Signaling Peptides and Proteins; D011480:Protease Inhibitors; D011971:Receptors, Immunologic; D011993:Recombinant Fusion Proteins; C114631:TNFSF13 protein, human; C505719:TNFSF13B protein, human; D014157:Transcription Factors; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13; D046988:Proteasome Endopeptidase Complex